Payment overview · 2025
General Payments
$257.23
13 reported records · 3 companies
Healthcare provider profile · identity verified
David Kieta, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · UNIONTOWN, PA · NPI 1194062109
Verified facts
What the public records show
CMS Open Payments records show David Kieta, CRNP received $257.23 in general payments during 2025 across 13 reported records.
ABBVIE INC. accounted for 52.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Vraylar by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $135.81 | 52.8% | 7 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $87.59 | 34.0% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.83 | 13.2% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $229.96 | 12 |
| Education | $27.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $135.81 | 7 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $87.59 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $33.83 | 2 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $33.83 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 109 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
109 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clonazepam | Clonazepam | 596 | 71 |
| Quetiapine Fumarate | Quetiapine Fumarate | 559 | 54 |
| Benztropine Mesylate | Benztropine Mesylate | 541 | 61 |
| Trazodone Hcl | Trazodone Hcl | 527 | 74 |
| Buspirone Hcl | Buspirone Hcl | 454 | 57 |
| Sertraline Hcl | Sertraline Hcl | 437 | 48 |
| Fluoxetine Hcl | Fluoxetine Hcl | 422 | 49 |
| Clozapine | Clozapine | 382 | 33 |
| Olanzapine | Olanzapine | 351 | 34 |
| Invega Sustenna | Paliperidone Palmitate | 347 | 42 |
| Gabapentin | Gabapentin | 346 | 44 |
| Risperidone | Risperidone | 309 | 32 |
| Mirtazapine | Mirtazapine | 287 | 37 |
| Divalproex Sodium Er | Divalproex Sodium | 277 | 29 |
| Lamotrigine | Lamotrigine | 246 | 28 |
| Divalproex Sodium | Divalproex Sodium | 213 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 199 | 26 |
| Lorazepam | Lorazepam | 194 | 22 |
| Bupropion Xl | Bupropion Hcl | 192 | 20 |
| Perphenazine | Perphenazine | 190 | 18 |
| Ziprasidone Hcl | Ziprasidone Hcl | 180 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 172 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 165 | 26 |
| Aripiprazole | Aripiprazole | 161 | 29 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 157 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 147 | 19 |
| Alprazolam | Alprazolam | 141 | 22 |
| Clonidine Hcl | Clonidine Hcl | 141 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 136 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 132 | 21 |
| Topiramate | Topiramate | 129 | 14 |
| Haloperidol | Haloperidol | 118 | 12 |
| Doxepin Hcl | Doxepin Hcl | 117 | 18 |
| Naltrexone Hcl | Naltrexone Hcl | 115 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 18 |
| Vraylar | Cariprazine Hcl | 109 | 15 |
| Prazosin Hcl | Prazosin Hcl | 107 | 16 |
| Propranolol Hcl | Propranolol Hcl | 101 | 17 |
| Oxcarbazepine | Oxcarbazepine | 90 | 15 |
| Lithium Carbonate | Lithium Carbonate | 88 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 76 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 66 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 62 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 61 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 57 | suppressed |
| Amantadine | Amantadine Hcl | 55 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 54 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 51 | suppressed |
| Abilify Maintena | Aripiprazole | 49 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 49 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 46 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 46 | suppressed |
| Paliperidone Er | Paliperidone | 45 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 43 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 42 | suppressed |
| Invega Trinza | Paliperidone Palmitate | 41 | 13 |
| Aristada | Aripiprazole Lauroxil | 39 | suppressed |
| Carbamazepine | Carbamazepine | 36 | suppressed |
| Fetzima | Levomilnacipran Hcl | 34 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 32 | suppressed |
| Rexulti | Brexpiprazole | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 13 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 12 | suppressed |
| Dexmethylphenidate Hcl Er | Dexmethylphenidate Hcl | 12 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 12 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Zoloft | Sertraline Hcl | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $257.23 · 13 records | ABBVIE INC. | COBENFY, FANAPT, HETLIOZ, VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error